Didn't have to happen. Shouldn't have happened if
Post# of 142806
If the analysts were doing their jobs, a lot more people would know about Leronlimab. They'd have proper funding. Families would have more hope and lives would have been saved sooner.
Plain silly to ignore clinical trial results just because a company isn't listed on the Nasdaq or NYSE.